![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Biosimilar Inflectra Snags FDA Approval
Biosimilar Inflectra Snags FDA Approval
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
The FDA has approved Celltrion’s Inflectra, making it the second biosimilar in the U.S.
A biosimilar of Janssen Biotech’s Remicade, Inflectra is approved for several indications: adult and pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondylitis, active psoriatic arthritis and chronic severe plaque psoriasis.
Inflectra — which will be marketed in the U.S. by Pfizer — contains a boxed warning about a risk of serious infections, including tuberculosis, bacterial sepsis and invasive fungal infections that could lead to hospitalization or death. It is not approved as an interchangeable product.
Upcoming Events
-
21Oct